S&P 500   3,383.25 (+1.49%)
DOW   27,952.84 (+0.96%)
QQQ   272.58 (+2.79%)
AAPL   452.83 (+3.50%)
MSFT   210.04 (+3.27%)
FB   261.42 (+2.07%)
GOOGL   1,509.58 (+1.96%)
AMZN   3,166.51 (+2.79%)
NVDA   456.92 (+5.28%)
CGC   17.40 (+2.65%)
BABA   255.54 (+2.87%)
TSLA   1,552.82 (+12.98%)
GE   6.63 (-1.49%)
MU   48.58 (+1.72%)
AMD   82.44 (+7.23%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.86 (-1.60%)
GILD   68.89 (+1.16%)
NFLX   480.44 (+2.89%)
DIS   131.35 (+0.66%)
BAC   26.62 (-1.11%)
BA   173.96 (-3.43%)
S&P 500   3,383.25 (+1.49%)
DOW   27,952.84 (+0.96%)
QQQ   272.58 (+2.79%)
AAPL   452.83 (+3.50%)
MSFT   210.04 (+3.27%)
FB   261.42 (+2.07%)
GOOGL   1,509.58 (+1.96%)
AMZN   3,166.51 (+2.79%)
NVDA   456.92 (+5.28%)
CGC   17.40 (+2.65%)
BABA   255.54 (+2.87%)
TSLA   1,552.82 (+12.98%)
GE   6.63 (-1.49%)
MU   48.58 (+1.72%)
AMD   82.44 (+7.23%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.86 (-1.60%)
GILD   68.89 (+1.16%)
NFLX   480.44 (+2.89%)
DIS   131.35 (+0.66%)
BAC   26.62 (-1.11%)
BA   173.96 (-3.43%)
S&P 500   3,383.25 (+1.49%)
DOW   27,952.84 (+0.96%)
QQQ   272.58 (+2.79%)
AAPL   452.83 (+3.50%)
MSFT   210.04 (+3.27%)
FB   261.42 (+2.07%)
GOOGL   1,509.58 (+1.96%)
AMZN   3,166.51 (+2.79%)
NVDA   456.92 (+5.28%)
CGC   17.40 (+2.65%)
BABA   255.54 (+2.87%)
TSLA   1,552.82 (+12.98%)
GE   6.63 (-1.49%)
MU   48.58 (+1.72%)
AMD   82.44 (+7.23%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.86 (-1.60%)
GILD   68.89 (+1.16%)
NFLX   480.44 (+2.89%)
DIS   131.35 (+0.66%)
BAC   26.62 (-1.11%)
BA   173.96 (-3.43%)
S&P 500   3,383.25 (+1.49%)
DOW   27,952.84 (+0.96%)
QQQ   272.58 (+2.79%)
AAPL   452.83 (+3.50%)
MSFT   210.04 (+3.27%)
FB   261.42 (+2.07%)
GOOGL   1,509.58 (+1.96%)
AMZN   3,166.51 (+2.79%)
NVDA   456.92 (+5.28%)
CGC   17.40 (+2.65%)
BABA   255.54 (+2.87%)
TSLA   1,552.82 (+12.98%)
GE   6.63 (-1.49%)
MU   48.58 (+1.72%)
AMD   82.44 (+7.23%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.86 (-1.60%)
GILD   68.89 (+1.16%)
NFLX   480.44 (+2.89%)
DIS   131.35 (+0.66%)
BAC   26.62 (-1.11%)
BA   173.96 (-3.43%)
Log in

NASDAQ:CBDCApotheca Biosciences Stock Price, Forecast & News

$0.01
-0.02 (-60.00 %)
(As of 08/12/2020 09:30 AM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range
$0.01
MA: $0.02
$0.03
52-Week Range
$0.00
Now: $0.01
$0.15
Volume31,740 shs
Average Volume17,081 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Apotheca Biosciences, Inc. develops cutting-edge medical products, nutraceuticals, formulation, and delivery technologies for the healthcare and consumer care industry. The company is based in the United States.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBDC
CUSIPN/A
CIKN/A
WebN/A
Phone727-228-3994

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
$0.01
-0.02 (-60.00 %)
(As of 08/12/2020 09:30 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CBDC News and Ratings via Email

Sign-up to receive the latest news and ratings for CBDC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Apotheca Biosciences (NASDAQ:CBDC) Frequently Asked Questions

How has Apotheca Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Apotheca Biosciences' stock was trading at $0.0190 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CBDC shares have decreased by 47.4% and is now trading at $0.01.
View which stocks have been most impacted by Coronavirus
.

Has Apotheca Biosciences been receiving favorable news coverage?

News coverage about CBDC stock has trended negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Apotheca Biosciences earned a news sentiment score of -2.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.
View the latest news about Apotheca Biosciences
.

Who are some of Apotheca Biosciences' key competitors?

What other stocks do shareholders of Apotheca Biosciences own?

Who are Apotheca Biosciences' key executives?

Apotheca Biosciences' management team includes the following people:
  • Dr. P. C. Sundareswaran, Chairman, CEO & CFO
  • Ms. Deirdre Fernandes, COO & Director
  • Mr. John Verghese, CTO & Director (Age 58)
  • Mr. Craig Huffman, Legal Council
  • Karin Rohret, Sec.

What is Apotheca Biosciences' stock symbol?

Apotheca Biosciences trades on the NASDAQ under the ticker symbol "CBDC."

How do I buy shares of Apotheca Biosciences?

Shares of CBDC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Apotheca Biosciences' stock price today?

One share of CBDC stock can currently be purchased for approximately $0.01.

How can I contact Apotheca Biosciences?

The company can be reached via phone at 727-228-3994.

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.